Ceralasertib + Olaparib for fallopian tube neoplasms

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 6 Jul 2018: Trial registered, NCT03579316
  2. 7 Dec 2018: Trial started, NCT03579316

The trials

NCT03579316: Adavosertib With or Without Olaparib in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

State
Under way
Phase
Phase 2
People
96 taking part
Started
7 Dec 2018
Primary completion
31 Dec 2026
Arms
Arm III (ceralasertib, olaparib)
Results
None posted
  1. 6 Jul 2018: Trial registered
  2. 7 Dec 2018: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.